SI-BONE (SIBN) to Release Quarterly Earnings on Monday

SI-BONE (NASDAQ:SIBN) is scheduled to post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect SI-BONE to post earnings of ($0.29) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $38.86 million for the quarter, compared to analyst estimates of $38.60 million. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Performance

Shares of SIBN stock opened at $14.20 on Friday. SI-BONE has a one year low of $14.07 and a one year high of $29.51. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.01 and a quick ratio of 8.15. The firm has a 50-day moving average of $16.11 and a 200-day moving average of $18.05. The company has a market cap of $585.04 million, a P/E ratio of -12.46 and a beta of 1.24.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SIBN. Morgan Stanley raised their price target on shares of SI-BONE from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 27th. Truist Financial restated a “buy” rating and set a $24.00 target price (down previously from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 target price on shares of SI-BONE in a report on Wednesday, April 3rd. Finally, Piper Sandler began coverage on shares of SI-BONE in a research note on Thursday, March 28th. They set an “overweight” rating and a $25.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE presently has an average rating of “Buy” and a consensus target price of $26.67.

Insider Activity

In related news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the sale, the chief financial officer now directly owns 205,516 shares in the company, valued at approximately $3,175,222.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total value of $37,466.25. Following the sale, the chief financial officer now owns 205,516 shares of the company’s stock, valued at approximately $3,175,222.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mika Nishimura sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total value of $40,550.00. Following the transaction, the director now directly owns 19,350 shares of the company’s stock, valued at approximately $313,857. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,905 shares of company stock valued at $190,273. Corporate insiders own 5.40% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.